BrainXell

About BrainXell

BrainXell, headquartered in Madison, WI, specializes in producing high purity, induced pluripotent stem cell (iPSC)-derived human neurons for research and drug discovery. Founded in 2015 by Prof. Su Chun Zhang through the University of Wisconsin Madison's Discovery to Product (D2P) program, BrainXell leverages proprietary technology to create highly enriched subclasses of neurons. The company serves pharmaceutical companies, biotech firms, and academic researchers who require reliable and reproducible neuronal cell models for various applications, including high throughput screens, electrophysiology, calcium assays, and 3D neural spheroids. Operating in the drug discovery market, BrainXell's business model revolves around the sale of these specialized neuronal cultures, which are critical for improving the clinical relevance of early-stage drug discovery and increasing the likelihood of clinical success. The company generates revenue through direct sales of its neuronal cultures and related services.